Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-07-28

FDA Approved: NULOJIX — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

FDA approved a supplemental application for NULOJIX (belatacept) submitted by E.R. Squibb & Sons, L.L.C., related to its use in kidney transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nulojix (belatacept)

Snippet

SUPPL AP for NULOJIX (BELATACEPT)